New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
The filing is backed by results from the pivotal SERENA-6 Phase III trial
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
Subscribe To Our Newsletter & Stay Updated
